Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $923000.0.

  • Allogene Therapeutics' Amortizatization of Intangibles fell 4567.39% to $923000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 4946.98%. This contributed to the annual value of $8.3 million for FY2024, which is 2260.24% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Amortizatization of Intangibles of $923000.0 as of Q3 2025, which was down 4567.39% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Amortizatization of Intangibles peaked at $3.3 million during Q4 2023, and registered a low of -$1.9 million during Q1 2021.
  • In the last 5 years, Allogene Therapeutics' Amortizatization of Intangibles had a median value of $923000.0 in 2025 and averaged $458473.7.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 317678.57% in 2021, then soared by 221474.36% in 2023.
  • Allogene Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$1.6 million in 2021, then soared by 90.21% to -$156000.0 in 2022, then soared by 2214.74% to $3.3 million in 2023, then crashed by 49.95% to $1.7 million in 2024, then tumbled by 44.09% to $923000.0 in 2025.
  • Its Amortizatization of Intangibles was $923000.0 in Q3 2025, compared to $1.2 million in Q2 2025 and $1.3 million in Q1 2025.